EADV Podcast

E42: Changing Treatment Landscape in Psoriasis

Listen Later

This week Dr. Mark Lebwohl from Icahn School of Medicine at Mount Sinai joins us to discuss the latest treatment options for psoriasis and his research focusing on new topical therapies for the management of the disease.

 

Links to the six articles discussed can be found here:

  • Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
  • Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
  • Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study
  • Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis
  • Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion inmoderate-to-severe plaque psoriasis: phase 3 open-label study
  • Itch: an under-recognized problem in psoriasis
    • ...more
    View all episodesView all episodes
    Download on the App Store
    EADV PodcastBy EADV
    • 5
    • 5
    • 5
    • 5
    • 5

    5

    2 ratings

    More shows like EADV Podcast

    View all
    TED Talks Daily by TED

    TED Talks Daily

    11,159 Listeners

    JAMA Clinical Reviews by JAMA Network

    JAMA Clinical Reviews

    499 Listeners

    Harrison's PodClass: Internal Medicine Cases and Board Prep by AccessMedicine

    Harrison's PodClass: Internal Medicine Cases and Board Prep

    365 Listeners